At the Experimental Nuclear Magnetic Resonance Conference (ENC), Bruker Corporation today announced new NMR products and workflow solutions designed to expand performance, sensitivity and automation across research and applied NMR. Implementations span console electronics, quantitative chemistry, benchtop FT-NMR, solid-state and solution dynamic nuclear polarization (DNP), and digital workflows supporting reproducible, unattended, data-driven automation.
Advanced Chemical Profiling 2.0 enables a fully automated workflow. Image credit: Bruker Corporation
High-performance AVANCE NEO‑X NMR electronics allow laboratories to upgrade console generations without disrupting established workflows. The AVANCE NEO‑X console supports liquid, solid state, and microimaging NMR with a modular design that accommodates evolving experimental requirements.
For quantitative NMR in chemistry, small molecule pharmaceuticals, and industrial applications, next-generation Advanced Chemical Profiling 2.0 (ACP 2.0) software provides an automated acquisition-to-report workflow. ACP 2.0 supports accurate quantification of multicomponent spectra across Bruker benchtop and high-field NMR systems by reducing manual interpretation.
The Fourier 80 Duo establishes 80 MHz as an affordable standard for labs transitioning from 60 MHz equipment. The benchtop Fourier 80 Duo provides high-quality 1D/2D FT-NMR spectra for chemistry with gradient 1H/13C, solvent suppression, and inverse spectroscopy capabilities.
Bruker is expanding its DNP portfolio with 600 MHz and 800 MHz standard bore magnets and a new standard bore DNP probe for solid-state NMR that enables ultra-high sensitivity in 1.0 GHz and 1.2 GHz systems. These technically highly demanding SB-DNP probes support biosolids applications with HCN designs and extend high-field solid-state DNPs for materials applications through fixed channel configurations. Complementing these solid-state DNP capabilities, the Dynamis soluble DNP system enables liquid applications that are not practical with traditional sensitivity limits. Dynamis supports reproducible, higher-throughput solution-state NMR and metabolic MRI studies in catalysis or chemical kinetics with up to 30,000x 13C signal enhancement and 5x to 10x faster polarization.
Bruker is also introducing enhanced NMR solutions for structural biology, laboratory automation, data-driven research and analytical workflows. NMRtist provides AI-assisted protein NMR data analysis, from multidimensional peak picking to resonance assignment and structure calculations, even if you are not an NMR expert. New RNA Drug Discovery with NMR Toolkit provides access to optimized experiments, guided workflows, and resources for RNA structure, dynamics, binding studies, and RNA modification analysis. NMR is the gold standard for solving RNA structures. In solid-state NMR, 160 kHz magic angle spinning (MAS) solutions enable high-resolution HCN studies of membrane proteins, protein aggregates, and complex biological assemblies.
Chemspeed automation solutions support scalable, unattended NMR automation by combining standardized sample preparation, automated synthesis or sampling, and online or offline NMR analysis to increase throughput and reduce manual operations. SciY software solutions power small molecule data processing and lab digitization through a vendor-independent backbone that connects instrumentation, automation, and data systems to support traceable workflows, FAIR-enabled data, and data-driven decision-making across AI-assisted or AI-driven R&D or quality control labs.
Our introduction of ENC 2026 reflects our focus on impactful innovation through NMR technology and workflows designed to improve productivity, performance, and ease of use to deliver reproducible research and applied results.
These advances will further increase the impact of laboratories to work efficiently, automate complex tasks, and generate unique, high-value NMR insights to complement other methods in structural biology, molecular dynamics, biocondensates, disordered proteins, membrane proteins and aggregates, as well as chemical and small molecule applications, pharmaceutical and industrial applications. ”
Dr. Frank H. Laukien, President and CEO, Bruker Corporation
